45 MNOK to innovative cancer treatments and diagnostics

The Norwegian Research Council and Norwegian Cancer Society are teaming up to make the results of medical and biotechnical research faster available for cancer patients.

The call on 45 MNOK will be administered through the Research Council’s program for biotechnology (BIOTEK21) and commercialization (FORNY2020).

– This is an exciting and unique collaboration between the Norwegian Cancer Society and the Norwegian Research Council. There is a long way from scientific idea to finished product. The process before the product is on the market and used by many patients are demanding and costly. These funds will provide important impetus to future-oriented Norwegian research. There is enormous potential in research and innovation in health, says the Norwegian Cancer Society General Anne Lise Ryel.

Arvid Hallén, CEO of the Norwegian Research Council agrees:

– I think it can mean much that the Norwegian Cancer Society and the Norwegian Research Council will work together on this. To be successful it is important that we also work closely with Norwegian companies that develop products and services for cancer diagnosis and cancer treatment. Fortunately, we have not only excellent researchers and clinics in health and biomedicine, we also have many companies that have shown that they can develop innovative products and services that can help cancer patients, says Hallén.

Applicants for this call will be commercial players who are affiliated research institutions. The announcement will be available on the Research Council’s website from the end of June and has a deadline of 9 September.

Find more information here: